Pages that link to "Q57395959"
Jump to navigation
Jump to search
The following pages link to In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo (Q57395959):
Displaying 50 items.
- Targeting neuropilin-1 in human leukemia and lymphoma (Q24620098) (← links)
- NRP1 function and targeting in neurovascular development and eye disease (Q26765952) (← links)
- Neuropilins and liver (Q27024032) (← links)
- Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. (Q33847973) (← links)
- Do Stress Responses Promote Leukemia Progression? An Animal Study Suggesting a Role for Epinephrine and Prostaglandin-E2 through Reduced NK Activity (Q33895068) (← links)
- Functional proteomic profiling of AML predicts response and survival (Q34184598) (← links)
- Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells (Q34353406) (← links)
- Contribution of bone microenvironment to leukemogenesis and leukemia progression (Q35037058) (← links)
- Biopolymeric delivery matrices for angiogenic growth factors. (Q35589939) (← links)
- Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. (Q35728896) (← links)
- Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. (Q35800540) (← links)
- Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis (Q35808025) (← links)
- The potential role of vascular endothelial growth factor in the central nervous system (Q35939261) (← links)
- Neuropilin Functions as an Essential Cell Surface Receptor (Q36443978) (← links)
- Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey (Q36489766) (← links)
- Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A (Q36528775) (← links)
- c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations (Q36544653) (← links)
- Gene therapy targeting to tumor endothelium (Q36649681) (← links)
- Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis (Q36672180) (← links)
- Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? (Q36762575) (← links)
- A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration (Q36961818) (← links)
- Semaphorin signals on the road to cancer invasion and metastasis (Q37426239) (← links)
- Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3. (Q37496585) (← links)
- Current drug design to target the Semaphorin/Neuropilin/Plexin complexes (Q37509064) (← links)
- Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization (Q37622043) (← links)
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer (Q37874750) (← links)
- Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions (Q38022543) (← links)
- Vascular endothelial growth factor signaling in acute myeloid leukemia (Q38029546) (← links)
- Neuropilins: a new target for cancer therapy (Q38161356) (← links)
- Neuropilin 1: function and therapeutic potential in cancer (Q38165001) (← links)
- The emerging role of class-3 semaphorins and their neuropilin receptors in oncology (Q38256958) (← links)
- The potential of class 3 semaphorins as both targets and therapeutics in cancer (Q38272709) (← links)
- Neuropilin-1 as Therapeutic Target for Malignant Melanoma. (Q38532037) (← links)
- The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies (Q38675589) (← links)
- miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism (Q39039867) (← links)
- Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway (Q39060605) (← links)
- Significance of neuropilin-1 expression in acute myeloid leukemia (Q39198179) (← links)
- Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells (Q40019030) (← links)
- Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. (Q40071740) (← links)
- Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma (Q40090855) (← links)
- Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma (Q40367447) (← links)
- Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies (Q40411720) (← links)
- Antiangiogenic treatment with endostatin inhibits progression of AML in vivo (Q40414210) (← links)
- Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis (Q41556287) (← links)
- Soluble Flt-1 gene delivery in acute myeloid leukemic cells mediating a nonviral gene carrier (Q42182112) (← links)
- Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases (Q43447911) (← links)
- Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α (Q44605539) (← links)
- Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia (Q44740278) (← links)
- A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. (Q46931556) (← links)
- Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide (Q46966668) (← links)